Monograph Details
|
|
Neoplasms
> Antimicrotubule agents
|
|
TAXOL |
| Manufacturer |
|
Bristol-Myers Squibb |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Antimicrotubule agent. |
| Generic Name |
|
Paclitaxel 6mg/mL; soln for IV administration after dilution; contains Cremophor EL (polyoxyethylated castor oil), dehydrated alcohol. |
| Indications |
|
First-line therapy (in combination with cisplatin) and subsequent therapy for advanced carcinoma of the ovary. Adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. Breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. First-line treatment of non-small cell lung cancer in combination with cisplatin in patients who are not candidates for potentially curative surgery and/or radiation therapy. Second-line treatment of AIDS-related Kaposi's sarcoma. |
| Children |
|
Not recommended. |
| Adults |
|
See literature. Premedicate with corticosteroids, diphenhydramine, H2 antagonists. Previously untreated ovarian cancer: 175mg/m2 IV over 3 hours + cisplatin every 3 weeks; or 135mg/m2 IV over 24 hours + cisplatin every 3 weeks. Previously treated ovarian cancer: 135mg/m2 or 175mg/m2 IV over 3 hours every 3 weeks. Breast cancer (node-positive): 175mg/m2 IV over 3 hours every 3 weeks for 4 courses administered sequentially to doxorubicin-containing combination chemotherapy. Breast cancer (after failure of initial chemotherapy for metastatic disease or relapse): 175mg/m2 IV over 3 hours every 3 weeks. Non-small cell lung cancer: 135mg/m2 IV over 24 hours + cisplatin every 3 weeks. AIDS-related Kaposi's sarcoma: 135mg/m2 IV over 3 hours every 3 weeks; or 100mg/m2 IV over 3 hours every 2 weeks. Hepatic impairment or neutropenia: see literature for dose modifications. Do not treat if neutrophil count <1,500cells/mm3 (<1,000cells/mm3 with Kaposi's sarcoma) or platelets <100,000cells/mm3. |
| Contraindications |
|
Solid tumors: baseline neutrophil count <1,500cells/mm3. AIDS-related Kaposi's sarcoma: baseline neutrophil count <1,000cells/mm3. |
| Precautions |
|
Do frequent peripheral blood cell counts. Hepatic dysfunction. Conduction abnormalities: monitor cardiac function. Avoid extravasation. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended. |
| Interactions |
|
May potentiate or be potentiated by CYP2C8 or CYP3A4 substrates and/or inhibitors. Potentiated by cisplatin. May potentiate doxorubicin. |
| Adverse Reactions |
|
Bone marrow suppression (eg, neutropenia, leukopenia, thrombocytopenia, anemia), inj site reactions, infections, hypotension, bradycardia, hypersensitivity reactions (if severe, do not rechallenge), peripheral neuropathy, myalgia, arthralgia, GI upset, mucositis, alopecia, abnormal ECG, elevated liver enzymes. |
| How Supplied |
|
Multidose vial (5mL, 16.7mL, 50mL)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
